Making and distributing billions of vaccines fast is difficult to say the least – this is a new novel solution.


Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential Universityconnect, watch a keynote, or browse my blog.

As the global pandemic has gripped the world a race began to develop vaccines in record time, and then came the problem of making enough doses and having to distribute them to the billions of people around the world who needed them – something that almost every company and every country struggled with.


Smartphone app uses selfies to detect Pancreatic Cancer


Evidently having to make vaccines in the traditional way, and secure enough glass, viles, and manufacturing capacity to make them all was difficult. So, then began a new vaccine race – to develop vaccines that didn’t need to be injected, that could be breathed in or taken in pill form, and that protected against every kind of future Coronavirus strain. And now we’re nearing the finishing line with several trials nearing completion and Pfizer’s CEO Albert Bourla announcing that their experimental oral drug to treat Covid-19 at the first sign of illness could be available by the end of the year.

The company, which developed the first authorized Covid-19 vaccine in the US with German drug maker BioNTech, began trials in March. The drug is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme that the virus needs to replicate in human cells. Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.


Researchers successfully grow mini human livers from stem cells for first time


If clinical trials go well and, more importantly, the Food and Drug Administration approves it, the drug could be distributed across the US by the end of the year.

Health experts say the drug, taken by mouth, could be a game changer because people newly infected with the virus could use it outside of hospitals and could even be posted to patients. Researchers hope the medication will keep the disease from progressing and prevent hospital trips.

In addition to the drug Pfizer is still testing its vaccine in 6 month to 11 year old children. Vaccinating children is crucial to ending the coronavirus pandemic, public health officials and infectious disease experts say.


Scientists have reverse engineered the genome of a man who died 200 years ago


Earlier this month, the company asked the FDA to expand its vaccine authorization to adolescents ages 12 to 15 after the shot was found to be 100% effective in a study. Bourla says he is “very optimistic” that the FDA will approve use of the shot in adolescents.

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.

Your email address will not be published. Required fields are marked *